Australia's most trusted
source of pharma news
Friday, 05 June 2026
Posted 5 June 2026 AM
The PBAC's pricing model needs to change if increased biosimilar medicine usage is to attract launches of innovative medinces to Australia, according to a report by Sandoz.
Sandoz has released a Blueprint for Australian Medicines Access which outlines coordinated policies the Federal Government can introduce to increase the uptake of biosimilar medicines in Australia, after a consultation process was announced in last month's Budget.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.